Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2025.01.022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Rami Kotb und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Care Manitoba, Winnipeg, MB, Canada. Electronic address: rkotb@cancercare.mb.ca. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Isatuximab-based combinations are widely used to treat patients with relapsed or refractory multiple myeloma, and will soon become part of the standard first-line therapies in transplant-eligible and transplant-ineligible newly diagnosed patients. Isatuximab is currently approved for intravenous fixed volume (250ml) administration, with a maximum infusion rate of 200 ml/h and at least 75 minutes required for 1 administration. A recent clinical trial suggested the safety of a faster, 30-minute administration of isatuximab. Other trials are ongoing. Based on this early data as well as previous experience with monoclonal antibody therapies, the rapid, 30-minutes intravenous isatuximab administration was adopted at our institution as standard of care. METHODOLOGY: We here report the early real-world data on this new standard.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Care Manitoba, Winnipeg, MB, Canada. Electronic address: rkotb@cancercare.mb.ca.
- Cancer Care Manitoba, Winnipeg, MB, Canada.
Zitieren
APA
Kotb, R., Geirnaert, M., Rimmer, E., Dao, V., Kasian, J., Minuk, L., & Landego, I. (2025). Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.01.022
Vancouver
Kotb R, Geirnaert M, Rimmer E, Dao V, Kasian J, Minuk L, et al. Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.01.022
BibTeX
@article{Kotb2025,
author = {Kotb, Rami and Geirnaert, Marc and Rimmer, Emily and Dao, Vi and Kasian, Jayne and Minuk, Leonard and Landego, Ivan},
title = {Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2025.01.022}
}
EUVIMED